Marshall Wace LLP Takes Position in Sight Sciences, Inc. (NASDAQ:SGHT)

Marshall Wace LLP acquired a new position in shares of Sight Sciences, Inc. (NASDAQ:SGHT) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 26,300 shares of the company’s stock, valued at approximately $96,000. Marshall Wace LLP owned about 0.05% of Sight Sciences at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in SGHT. Dynamic Technology Lab Private Ltd bought a new position in Sight Sciences during the 4th quarter worth approximately $40,000. Arkadios Wealth Advisors bought a new position in Sight Sciences during the fourth quarter worth $47,000. WealthTrust Asset Management LLC acquired a new position in Sight Sciences in the fourth quarter valued at $48,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in Sight Sciences in the fourth quarter valued at $50,000. Finally, Stoneridge Investment Partners LLC bought a new stake in Sight Sciences during the fourth quarter valued at $55,000. 55.51% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Sight Sciences

In other news, CEO Paul Badawi sold 24,174 shares of the business’s stock in a transaction that occurred on Tuesday, April 1st. The stock was sold at an average price of $2.30, for a total value of $55,600.20. Following the transaction, the chief executive officer now owns 6,010,580 shares in the company, valued at $13,824,334. The trade was a 0.40 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Manohar K. Raheja bought 10,000 shares of Sight Sciences stock in a transaction dated Wednesday, March 12th. The stock was acquired at an average cost of $2.73 per share, with a total value of $27,300.00. Following the completion of the acquisition, the executive vice president now owns 145,000 shares of the company’s stock, valued at $395,850. This represents a 7.41 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold a total of 35,196 shares of company stock valued at $81,001 over the last 90 days. Insiders own 28.90% of the company’s stock.

Sight Sciences Stock Performance

SGHT opened at $2.81 on Wednesday. Sight Sciences, Inc. has a 1-year low of $2.03 and a 1-year high of $8.45. The company has a market cap of $145.27 million, a price-to-earnings ratio of -2.75 and a beta of 2.41. The company’s fifty day moving average price is $2.66 and its two-hundred day moving average price is $3.28. The company has a current ratio of 10.18, a quick ratio of 9.74 and a debt-to-equity ratio of 0.36.

Sight Sciences (NASDAQ:SGHT) last posted its earnings results on Wednesday, March 5th. The company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.01). The business had revenue of $19.07 million during the quarter, compared to analyst estimates of $18.98 million. Sight Sciences had a negative return on equity of 47.28% and a negative net margin of 63.30%. During the same quarter in the prior year, the company earned ($0.22) EPS. On average, analysts expect that Sight Sciences, Inc. will post -0.99 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on SGHT. UBS Group dropped their price objective on Sight Sciences from $5.50 to $5.00 and set a “buy” rating on the stock in a research note on Monday, January 27th. Stifel Nicolaus reduced their price objective on shares of Sight Sciences from $5.00 to $4.00 and set a “buy” rating for the company in a research report on Thursday, March 6th. Needham & Company LLC reiterated a “hold” rating on shares of Sight Sciences in a research report on Wednesday, April 9th. Piper Sandler reduced their price target on shares of Sight Sciences from $5.50 to $3.50 and set a “neutral” rating for the company in a report on Thursday, March 6th. Finally, Citigroup cut their price objective on shares of Sight Sciences from $4.60 to $3.00 and set a “neutral” rating on the stock in a research report on Tuesday, March 4th. Five research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $3.83.

Sight Sciences Company Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.